Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Expanding coverage of the drugs would have ... In an effort to reduce costs, Medicare has selected Novo Nordisk’s Wegovy for negotiations to lower prices under a law passed by a Democratic ...

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like peptide-1 agonists) that have upended the ...

Eliminating coverage for these drugs ... Between 2022 and 2023, Wegovy prescriptions in the Medi-Cal program jumped from 15,000 to 181,000, data from the U.S. Centers for Medicaid and Medicare ...

whether Medicare coverage of Ozempic is the same as Wegovy, and whether other insurances cover Ozempic. With prediabetes, your blood sugar levels are higher than usual. But they’re not yet high ...